These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 23648144)

  • 1. Mechanistic / mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia.
    Hirao A; Hoshii T
    Cancer Sci; 2013 Aug; 104(8):977-82. PubMed ID: 23648144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Roles of mTOR signalings in hematopoiesis and leukemogenesis].
    Hirao A
    Rinsho Ketsueki; 2015 Jun; 56(6):601-5. PubMed ID: 26256868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. mTORC signaling in hematopoiesis.
    Wang X; Chu Y; Wang W; Yuan W
    Int J Hematol; 2016 May; 103(5):510-8. PubMed ID: 26791377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Regulation of cancer behavior mediated by mTOR signal].
    Hirao A
    Nihon Rinsho; 2015 May; 73(5):773-8. PubMed ID: 25985629
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of mTORC1-S6K1 signaling pathway in regulation of hematopoietic stem cell and acute myeloid leukemia.
    Ghosh J; Kapur R
    Exp Hematol; 2017 Jun; 50():13-21. PubMed ID: 28342808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S6K1 regulates hematopoietic stem cell self-renewal and leukemia maintenance.
    Ghosh J; Kobayashi M; Ramdas B; Chatterjee A; Ma P; Mali RS; Carlesso N; Liu Y; Plas DR; Chan RJ; Kapur R
    J Clin Invest; 2016 Jul; 126(7):2621-5. PubMed ID: 27294524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis.
    Kalaitzidis D; Sykes SM; Wang Z; Punt N; Tang Y; Ragu C; Sinha AU; Lane SW; Souza AL; Clish CB; Anastasiou D; Gilliland DG; Scadden DT; Guertin DA; Armstrong SA
    Cell Stem Cell; 2012 Sep; 11(3):429-39. PubMed ID: 22958934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temporal changes in PTEN and mTORC2 regulation of hematopoietic stem cell self-renewal and leukemia suppression.
    Magee JA; Ikenoue T; Nakada D; Lee JY; Guan KL; Morrison SJ
    Cell Stem Cell; 2012 Sep; 11(3):415-28. PubMed ID: 22958933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic roles of mTOR complexes in haemato-lymphopoiesis and leukemogenesis.
    Hoshii T; Matsuda S; Hirao A
    J Biochem; 2014 Aug; 156(2):73-83. PubMed ID: 24962700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Akt-mTOR network at the interface of hematopoietic stem cell homeostasis.
    Wu F; Chen Z; Liu J; Hou Y
    Exp Hematol; 2021 Nov; 103():15-23. PubMed ID: 34464661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapamycin enhances long-term hematopoietic reconstitution of ex vivo expanded mouse hematopoietic stem cells by inhibiting senescence.
    Luo Y; Li L; Zou P; Wang J; Shao L; Zhou D; Liu L
    Transplantation; 2014 Jan; 97(1):20-9. PubMed ID: 24092377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutrient signaling to mTOR and cell growth.
    Jewell JL; Guan KL
    Trends Biochem Sci; 2013 May; 38(5):233-42. PubMed ID: 23465396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
    Zou Z; Chen J; Yang J; Bai X
    Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.
    Tabe Y; Tafuri A; Sekihara K; Yang H; Konopleva M
    Expert Opin Ther Targets; 2017 Jul; 21(7):705-714. PubMed ID: 28537457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanistic target of rapamycin complex 2 protects the heart from ischemic damage.
    Völkers M; Konstandin MH; Doroudgar S; Toko H; Quijada P; Din S; Joyo A; Ornelas L; Samse K; Thuerauf DJ; Gude N; Glembotski CC; Sussman MA
    Circulation; 2013 Nov; 128(19):2132-44. PubMed ID: 24008870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Amino acid-insensitive mTORC1 regulation enables nutritional stress resilience in hematopoietic stem cells.
    Kalaitzidis D; Lee D; Efeyan A; Kfoury Y; Nayyar N; Sykes DB; Mercier FE; Papazian A; Baryawno N; Victora GD; Neuberg D; Sabatini DM; Scadden DT
    J Clin Invest; 2017 Apr; 127(4):1405-1413. PubMed ID: 28319048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PTEN in the haematopoietic system and its therapeutic indications.
    Cheung AM; Mak TW
    Trends Mol Med; 2006 Nov; 12(11):503-5. PubMed ID: 16996801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A complex interplay between PGC-1 co-activators and mTORC1 regulates hematopoietic recovery following 5-fluorouracil treatment.
    Basu S
    Stem Cell Res; 2014 Jan; 12(1):178-93. PubMed ID: 24239965
    [TBL] [Abstract][Full Text] [Related]  

  • 20. mTOR activation induces tumor suppressors that inhibit leukemogenesis and deplete hematopoietic stem cells after Pten deletion.
    Lee JY; Nakada D; Yilmaz OH; Tothova Z; Joseph NM; Lim MS; Gilliland DG; Morrison SJ
    Cell Stem Cell; 2010 Nov; 7(5):593-605. PubMed ID: 21040901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.